| Gene symbol | IL12A | Synonyms | CLMF, IL-12A, NFSK, NKSF1, P35 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q25.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | interleukin 12A | ||||
| Gene symbol | IL12B | Synonyms | CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2 | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q33.3 | dbXrefs | |
| Description | interleukin 12B | ||||
| GTO ID | GTC1314 |
| Trial ID | NCT00849459 |
| Disease | Breast Cancer |
| Altered gene | IL-12A|IL-12B |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | AdV-hIL12 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer |
| Year | 2009 |
| Country | United States |
| Company sponsor | Icahn School of Medicine at Mount Sinai |
| Other ID(s) | GCO 02-0797|MTS-GCO-02-0797|NIH-0707-869|CDR0000629819 |
| Vector information | |||||||||
|
|||||||||
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||
| Cohort3: dose level 3 | |||||||
|
|||||||
| Cohort4: dose level 4 | |||||||
|
|||||||